	US 12,461,112 B2
	Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
Timothy E. Van Meter, Richmond, VA (US); and Nazanin Mirshahi, Richmond, VA (US)
Assigned to Brainbox Solutions, Inc., Richmond, VA (US)
Filed by BRAINBOX SOLUTIONS, INC., Richmond, VA (US)
Filed on Jun. 6, 2023, as Appl. No. 18/329,892.
Application 18/329,892 is a division of application No. 16/616,051, granted, now 11,709,168, previously published as PCT/US2018/033943, filed on May 22, 2018.
Claims priority of provisional application 62/532,180, filed on Jul. 13, 2017.
Claims priority of provisional application 62/510,096, filed on May 23, 2017.
Prior Publication US 2023/0314453 A1, Oct. 5, 2023
Int. Cl. G01N 33/68 (2006.01); A61B 5/00 (2006.01)

CPC G01N 33/6896 (2013.01) [A61B 5/4064 (2013.01); G01N 2800/28 (2013.01)]

14 Claims

1. A method of measuring one or more biomarkers and neuroimaging one or more fiber tracts in the brain of an individual suspected to have brain injury, the method comprising the steps of:

a. measuring levels of one or more brain specific protein biomarkers selected from Neurogranin (NRGN) and/or Glial Fibrillary Acidic Protein (GFAP) in a biological sample obtained from the individual;

b. neuroimaging the individual to visualize fiber tracts in the brain when the levels of one or more of the biomarker proteins in the sample are altered relative to respective control levels using a specialized neuroimaging technique; and

c. detecting changes in one or more fiber tracts in the brain relative to a control.